Research output: Contribution to journal › Review article › peer-review
КЛЕТОЧНЫЙ ПРЕПАРАТ С ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ NKG2D В CAR T-ТЕРАПИИ РЕЦИДИВОВ/РЕФРАКТЕРНЫХ ОСТРЫХ МИЕЛОИДНЫХ ЛЕЙКОЗОВ И МИЕЛОДИСПЛАСТИЧЕСКОГО СИНДРОМА. / Левчук, Ксения Александровна; Белоцерковская, Екатерина; Поздняков, Данила Юрьевич; Гиршова, Лариса; Зарицкий, А.Ю. ; Петухов, Алексей Вячеславович.
In: Klinicheskaya Onkogematologiya/Clinical Oncohematology, Vol. 14, No. 1, 2021, p. 138-148.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - КЛЕТОЧНЫЙ ПРЕПАРАТ С ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ NKG2D В CAR T-ТЕРАПИИ РЕЦИДИВОВ/РЕФРАКТЕРНЫХ ОСТРЫХ МИЕЛОИДНЫХ ЛЕЙКОЗОВ И МИЕЛОДИСПЛАСТИЧЕСКОГО СИНДРОМА
AU - Левчук, Ксения Александровна
AU - Белоцерковская, Екатерина
AU - Поздняков, Данила Юрьевич
AU - Гиршова, Лариса
AU - Зарицкий, А.Ю.
AU - Петухов, Алексей Вячеславович
PY - 2021
Y1 - 2021
N2 - NK-cells as innate immunity elements manifest key reactions of antitumor immune response. NKG2D is an activating transmembrane receptor of NK-cells which is responsible for cytotoxicity initiation in response to the binding of specific ligands of genetically modified cells. Selective expression of NKG2D ligands provides a unique perspective on the therapy of wide variety of tumors. Acute myeloid leukemias (AML) are malignant hematological tumors with a high relapse risk. Due to the complexity of AML treatment strategy it is necessary to develop new approaches to tumor elimination using novel genetic constructs. Currently available CAR T-cell drugs with NKG2D receptor are successfully subjected to clinical studies in AML patients and prove their high therapeutic potential.
AB - NK-cells as innate immunity elements manifest key reactions of antitumor immune response. NKG2D is an activating transmembrane receptor of NK-cells which is responsible for cytotoxicity initiation in response to the binding of specific ligands of genetically modified cells. Selective expression of NKG2D ligands provides a unique perspective on the therapy of wide variety of tumors. Acute myeloid leukemias (AML) are malignant hematological tumors with a high relapse risk. Due to the complexity of AML treatment strategy it is necessary to develop new approaches to tumor elimination using novel genetic constructs. Currently available CAR T-cell drugs with NKG2D receptor are successfully subjected to clinical studies in AML patients and prove their high therapeutic potential.
KW - Acute myeloid leukemias
KW - Adoptive therapy
KW - Chimeric antigen receptor
KW - NK-cells
KW - NKG2D
KW - Acute myeloid leukemias
KW - Adoptive therapy
KW - Chimeric antigen receptor
KW - NK-cells
KW - NKG2D
UR - https://elibrary.ru/item.asp?id=44768995
UR - http://www.scopus.com/inward/record.url?scp=85109301732&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/ae167c7b-396c-3af2-b6f3-43ab8baccbda/
U2 - 10.21320/2500-2139-2021-14-1-138-148
DO - 10.21320/2500-2139-2021-14-1-138-148
M3 - Обзорная статья
VL - 14
SP - 138
EP - 148
JO - Klinicheskaya Onkogematologiya/Clinical Oncohematology
JF - Klinicheskaya Onkogematologiya/Clinical Oncohematology
SN - 1997-6933
IS - 1
ER -
ID: 84919741